‘STRENGTHENING CAPABILITIES TO FULLY SERVICE BIOSIMILARS SEGMENT’

“We continue to see significant growth potential in generics with the long pipeline of products scheduled to go off-patent in the near to medium term. There is a significant development pipeline in biosimilars as well given scheduled patent expiries and we have been strengthening our capabilities to fully service this segment. We also see increasing potential for conducting late phase clinical trials in India across a spectrum of drug products and therapeutic areas, and have been investing in our team, processes and technology to support our global clientele in these.” - AJAY TANDON, Managing Director, Veeda Clinical Research, Ahmedabad